Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and ER-Stress-Targeted Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GRP78 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GRP78 (HSPA5) Recombinant Protein HEK293 expressed for native glycosylation, High Purity (>95%), Endotoxin Controlled, Sequence Verified. |
View GRP78 Products |
| Gene Delivery | GRP78 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and surface translocation assays. |
View GRP78 Products |
| Benchmark Ab | Anti-GRP78 Benchmark Antibody Recombinant positive control derived from clinical-stage sequences. |
View GRP78 Products |
| Validator | GRP78 siRNA Set Target-specific knockdown verification in phenotypic and functional assays. |
View GRP78 Products |
| Related Target A | HSPA8 (HSC70) High-homology cytosolic chaperone. Essential for selectivity and off-target toxicity counter-screening. |
View HSPA8 Products |
| Related Target B | CD147 (Basigin) Cell-surface interactor of GRP78. Crucial for validating csGRP78-mediated signaling and metastatic pathways. |
View CD147 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing cell-surface GRP78 (csGRP78) binders from intracellular pools | Lentivirus-driven stable overexpression combined with flow cytometry validation protocols. |
| High homology cross-reactivity with HSP70 family members (e.g., HSPA8) | Recombinant HSPA8 and other HSP family homolog proteins strictly verified by mass spectrometry for off-target counter-screening. |
| Lack of standardized positive controls | Sequence-verified clinical benchmark antibodies available as assay calibrators. |
| False positives in knockdown validation | Sequence-verified siRNA pools included to ensure specific target downregulation. |
Live GRP78 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GRP78 therapeutics is intensifying, with major players shifting focus from traditional intracellular chaperone inhibition to cell-surface GRP78 (csGRP78) targeting. As first-generation small molecule inhibitors of the ATPase domain face toxicity hurdles due to systemic chaperone inhibition, the next wave of R&D is targeting tumor-specific csGRP78 using Antibody-Drug Conjugates (ADCs), bispecific antibodies, and CAR-T cell therapies that exploit the selective translocation of GRP78 under microenvironmental stress.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Patrys, Academic Spin-offs | Solid Tumors, Triple-Negative Breast Cancer (TNBC) | Internalization Assay (Requires highly stable, native-glycosylated GRP78 recombinant protein). |
| Monoclonal / Bispecific Antibodies | Boehringer Ingelheim, Bio-Techne | Glioblastoma, Colorectal Cancer | Epitope mapping & cross-species reactivity (Requires sequence-verified Human and Cyno GRP78 proteins). |
| Small Molecule Inhibitors | Academic Consortia, Small Biotechs | Myeloma, Drug-Resistant Cancers | Selectivity assays (Requires HSPA8/HSPA1A panel proteins to screen against off-target HSP70 binding). |